HLA-DPA1: A Promising Drug Target / Biomarker (G3113)

Target Name: HLA-DPA1

NCBI ID: G3113

HLA-DPA1

HLA-DPA1: A Promising Drug Target / Biomarker

HLA-DPA1 is a human leukocyte antigen (HLA) that is expressed in various tissues throughout the body. It is a member of the DPA1 subfamily of the major histocompatibility complex (MHC), which is a group of genes that play a crucial role in the immune system. HLA-DPA1 is known for its ability to interact with the immune response, and it has been implicated in a number of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

Despite its potential as a drug target, HLA-DPA1 is still an poorly understood protein. There is limited research on the structure and function of HLA-DPA1, and there are few treatments that have been shown to effectively target this protein.

Structure and Function

HLA-DPA1 is a type I transmembrane protein that is expressed in various tissues throughout the body, including the skin, hair, and nervous system. It consists of a single constant (C) region, a variable (V) region, and an optional C-terminal region (T). The C region of HLA-DPA1 contains the major histocompatibility complex (MHC) genes, which encode the antigens that are recognized by the immune system.

The HLA-DPA1 protein is involved in the immune response by providing a surface for the presentation of antigens to T cells. This is accomplished through the use of the major histocompatibility complex (MHC) genes, which encode the antigens that are recognized by the immune system. HLA-DPA1 contains two MHC class I molecules, which are responsible for presenting antigens from the major histocompatibility complex (MHC) to T cells.

HLA-DPA1 has been shown to interact with the immune response in a number of ways. For example, HLA-DPA1 has been shown to interact with the adaptor protein PD-1, which is involved in the immune response. This interaction between HLA-DPA1 and PD-1 has been shown to promote the presentation of antigens to T cells.

HLA-DPA1 has also been shown to interact with the protein PD-L1. This interaction between HLA-DPA1 and PD-L1 has been shown to inhibit the immune response and promote the regulation of autoimmune diseases.

Despite its involvement in the immune response, HLA-DPA1 is not a well-targeted protein. There is limited research on the structure and function of HLA-DPA1, and there are few treatments that have been shown to effectively target this protein.

Drug Targeting

HLA-DPA1 is an attractive drug target due to its involvement in the immune response and its ability to interact with the immune response. There are several potential drugs that have been shown to target HLA-DPA1, including adoptive T cell therapy, cancer vaccines, and antibodies.

Adoptive T cell therapy is a promising approach to treating cancer, as it allows for the targeting of specific proteins that are involved in the development and progression of cancer. HLA-DPA1 is an ideal target for adoptive T cell therapy because of its involvement in the immune response and its ability to interact with the immune response.

Another potential drug for HLA-DPA1 is cancer vaccines. Cancer vaccines can be designed to stimulate an immune response against cancer cells, and HLA-DPA1 is an ideal target for cancer vaccines because of its involvement in the immune response.

Another approach to targeting HLA-DPA1 is the use of antibodies. HLA-DPA1 is a type I transmembrane protein, which means that it is able to interact with antibodies that are specific for HLA-DPA1. This makes HLA-DPA1 an

Protein Name: Major Histocompatibility Complex, Class II, DP Alpha 1

Functions: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading

The "HLA-DPA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-DPA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets